NASDAQ:AXDXAccelerate Diagnostics Stock Price, Forecast & News

Accelerate Diagnostics' stock was trading at $10.61 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AXDX stock has decreased by 20.0% and is now trading at $8.49. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Accelerate Diagnostics.

Accelerate Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Accelerate Diagnostics.

Accelerate Diagnostics Inc (NASDAQ:AXDX) released its earnings results on Thursday, May, 7th. The medical research company reported ($0.39) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.39). The medical research company earned $2.34 million during the quarter, compared to the consensus estimate of $2.40 million. Accelerate Diagnostics had a negative return on equity of 5,681.44% and a negative net margin of 845.43%. View Accelerate Diagnostics' earnings history.

Accelerate Diagnostics updated its first quarter 2020 After-Hours earnings guidance on Wednesday, April, 15th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.3-2.3 million, compared to the consensus revenue estimate of $2.32 million.

3 brokerages have issued twelve-month price targets for Accelerate Diagnostics' shares. Their forecasts range from $14.00 to $19.00. On average, they expect Accelerate Diagnostics' stock price to reach $16.33 in the next year. This suggests a possible upside of 92.4% from the stock's current price. View analysts' price targets for Accelerate Diagnostics.

Media headlines about AXDX stock have trended very positive this week, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Accelerate Diagnostics earned a news sentiment score of 3.5 on InfoTrie's scale. They also gave media headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutAccelerate Diagnostics.

Accelerate Diagnostics saw a increase in short interest in May. As of May 15th, there was short interest totaling 16,640,000 shares, an increase of 5.4% from the April 30th total of 15,780,000 shares. Based on an average daily volume of 447,000 shares, the short-interest ratio is currently 37.2 days. Approximately 52.9% of the company's stock are sold short. View Accelerate Diagnostics' Current Options Chain.

Some companies that are related to Accelerate Diagnostics include Quanterix (QTRX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Aethlon Medical (AEMD), Precipio (PRPO), Scientific Industries (SCND), Arrayit (ARYC), Pressure Biosciences (PBIO), Horiba (HRIBF) and PositiveID (PSID). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AbbVie (ABBV), AT&T (T) and Exelixis (EXEL).

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Accelerate Diagnostics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.64%), AXA (3.62%), Griffin Asset Management Inc. (2.52%), ArrowMark Colorado Holdings LLC (1.91%), Chicago Capital LLC (1.58%) and State Street Corp (1.09%). Company insiders that own Accelerate Diagnostics stock include Jack W Schuler, John Patience, Steven Reichling and Thomas D Brown. View institutional ownership trends for Accelerate Diagnostics.

AXDX stock was sold by a variety of institutional investors in the last quarter, including CSS LLC IL, Chicago Capital LLC, Morgan Stanley, Morgan Stanley, ArrowMark Colorado Holdings LLC, AXA, Parametric Portfolio Associates LLC, and Blair William & Co. IL. View insider buying and selling activity for Accelerate Diagnostics.

AXDX stock was acquired by a variety of institutional investors in the last quarter, including Griffin Asset Management Inc., BNP Paribas Arbitrage SA, Two Sigma Investments LP, Baird Financial Group Inc., Raging Capital Management LLC, Oxford Financial Group Ltd., Two Sigma Advisers LP, and State Street Corp. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler, John Patience, Steven Reichling, and Thomas D Brown. View insider buying and selling activity for Accelerate Diagnostics.

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AXDX stock can currently be purchased for approximately $8.49.

Accelerate Diagnostics has a market capitalization of $469.25 million and generates $9.30 million in revenue each year. The medical research company earns $-84,310,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. Accelerate Diagnostics employs 287 workers across the globe.

The official website for Accelerate Diagnostics is acceleratediagnostics.com.

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]